Literature DB >> 29288470

Assessing Racial Disparities in HCV Infection and Care Outcomes in a Southern Urban Population.

Keanan McGonigle1, Tess Carley2, Clarissa Hoff2.   

Abstract

OBJECTIVES: This study assessed racial disparities in access to healthcare services, hepatitis C virus (HCV) exposure, and retention in a treatment cascade in two indigent populations in an urban center in the Southern US. PARTICIPANTS/
METHODS: Opt-in HCV antibody screening was offered at two large homeless centers and three residential substance abuse treatment centers (SATCs) in New Orleans, LA. Five hundred ninety-four participants experiencing homelessness and 342 residents of SATCs were assessed for previous access/perceived barriers to healthcare services and high-risk behaviors associated with HCV exposure. Participants were then screened using rapid HCV antibody testing and tracked through a treatment cascade involving referral to a primary care provider (PCP), RNA confirmation, and specialist referral.
RESULTS: In both the homeless and SATC populations, whites were more likely to report barriers to accessing healthcare and high-risk behaviors, especially prior intravenous drug use (IVDU). Interaction between age and race demonstrates a protective effect of white ethnicity at higher ages, at a level approaching statistical significance. Non-whites were equally likely to access follow-up care and treatment as whites.
CONCLUSIONS: Despite many more risk factors reported by the white population, HCV antibody positivity was largely equal between the two racial groups. Known interactions between race and age in the African American population were demonstrated in these high-risk, urban populations. Whites were no more likely to achieve various levels of a treatment and care cascade. The results may demonstrate the impact of improved access to testing services and primary care, although access to treatment remains a significant barrier to eliminating racial disparities in HCV infection.

Entities:  

Keywords:  Hepatitis C virus; Homeless; Primary care retention; Race; Substance abuse

Mesh:

Substances:

Year:  2017        PMID: 29288470     DOI: 10.1007/s40615-017-0453-y

Source DB:  PubMed          Journal:  J Racial Ethn Health Disparities        ISSN: 2196-8837


  10 in total

Review 1.  Hepatitis C virus infection in African Americans.

Authors:  Brian L Pearlman
Journal:  Clin Infect Dis       Date:  2005-11-29       Impact factor: 9.079

2.  Mechanisms of action of interferon and ribavirin in chronic hepatitis C: Summary of a workshop.

Authors:  Raymond T Chung; Michael Gale; Stephen J Polyak; Stanley M Lemon; T Jake Liang; Jay H Hoofnagle
Journal:  Hepatology       Date:  2008-01       Impact factor: 17.425

Review 3.  A Systematic Review of Race and Ethnicity in Hepatitis C Clinical Trial Enrollment.

Authors:  Julius Wilder; Anirudh Saraswathula; Vic Hasselblad; Andrew Muir
Journal:  J Natl Med Assoc       Date:  2016-02       Impact factor: 1.798

Review 4.  Hepatitis C virus: Is it time to say goodbye yet? Perspectives and challenges for the next decade.

Authors:  Heidi Barth
Journal:  World J Hepatol       Date:  2015-04-18

5.  Racial differences in the evaluation and treatment of hepatitis C among veterans: a retrospective cohort study.

Authors:  Christine M Rousseau; George N Ioannou; Jeffrey A Todd-Stenberg; Kevin L Sloan; Meaghan F Larson; Christopher W Forsberg; Jason A Dominitz
Journal:  Am J Public Health       Date:  2008-04-01       Impact factor: 9.308

6.  Impact of race/ethnicity and gender on HCV screening and prevalence among U.S. veterans in Department of Veterans Affairs Care.

Authors:  Lisa I Backus; Pamela S Belperio; Timothy P Loomis; Larry A Mole
Journal:  Am J Public Health       Date:  2014-09       Impact factor: 9.308

Review 7.  An epidemiologic update on hepatitis C infection in persons living with or at risk of HIV infection.

Authors:  Arthur Y Kim; Shauna Onofrey; Daniel R Church
Journal:  J Infect Dis       Date:  2013-03       Impact factor: 5.226

8.  Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010.

Authors:  Maxine M Denniston; Ruth B Jiles; Jan Drobeniuc; R Monina Klevens; John W Ward; Geraldine M McQuillan; Scott D Holmberg
Journal:  Ann Intern Med       Date:  2014-03-04       Impact factor: 25.391

9.  All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study.

Authors:  Michael Manns; Stanislas Pol; Ira M Jacobson; Patrick Marcellin; Stuart C Gordon; Cheng-Yuan Peng; Ting-Tsung Chang; Gregory T Everson; Jeong Heo; Guido Gerken; Boris Yoffe; William J Towner; Marc Bourliere; Sophie Metivier; Chi-Jen Chu; William Sievert; Jean-Pierre Bronowicki; Dominique Thabut; Youn-Jae Lee; Jia-Horng Kao; Fiona McPhee; Justin Kopit; Patricia Mendez; Misti Linaberry; Eric Hughes; Stephanie Noviello
Journal:  Lancet       Date:  2014-07-28       Impact factor: 79.321

10.  Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US.

Authors:  Sai Zhang; Nathaniel D Bastian; Paul M Griffin
Journal:  BMC Gastroenterol       Date:  2015-08-05       Impact factor: 3.067

  10 in total
  1 in total

Review 1.  Barriers and facilitators to hepatitis C screening and treatment for people with lived experience of homelessness: A mixed-methods systematic review.

Authors:  Martha Paisi; Neeltje Crombag; Lorna Burns; Annick Bogaerts; Lyndsey Withers; Laura Bates; Daniel Crowley; Robert Witton; Jill Shawe
Journal:  Health Expect       Date:  2021-12-03       Impact factor: 3.377

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.